Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.45 |
| ▸ | TYMP | P19971 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | AHCY | P23526 | 4/20 | 0.44 |
| ▸ | NNMT | P40261 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.42 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14244154 | 0.92 | ADORA1 (0.45) | ADORA3ADORA1TRDMT1TYMPCARM1 | |
| SCHEMBL6835045 | 0.92 | ADORA1 (0.45) | ADORA3ADORA1TRDMT1TYMPCARM1 | |
| SCHEMBL17599855 | 0.91 | NT5E (0.49) | ADORA3ADORA1TRDMT1TYMPCARM1 | |
| SCHEMBL5218152 | 0.91 | ADORA3 (0.41) | ADORA3ADORA1TRDMT1TYMPCARM1 | |
| SCHEMBL17599879 | 0.89 | ADORA3 (0.48) | ADORA3ADORA1TRDMT1TYMPCARM1 | |
| SCHEMBL7266107 | 0.88 | ADORA1 (0.47) | ADORA1TRDMT1TYMPCARM1AHCY | |
| SCHEMBL5506246 | 0.86 | TYMP (0.41) | ADORA3ADORA1TRDMT1TYMPCARM1 | |
| SCHEMBL8144935 | 0.86 | ADORA1 (0.45) | ADORA3ADORA1TRDMT1TYMPCARM1 | |
| SCHEMBL2107506 | 0.86 | ADORA1 (0.53) | ADORA3ADORA1TRDMT1TYMPCARM1 | |
| SCHEMBL5348155 | 0.84 | CHKA (0.42) | ADORA1TRDMT1TYMPCARM1AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004131-B1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10669301-B2 | Phosphoramidite building blocks for sugar-conjugated oligonucleotides | AM CHEMICALS LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20180362572-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2018-12-20 | — | — | US | disclosed |
| US-10087208-B2 | Phosphoramidite building blocks for sugar-conjugated oligonucleotides | AM CHEMICALS LLC (US) | 2018-10-02 | — | — | US | disclosed |
| US-20160083414-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | AM CHEMICALS LLC (US) | 2016-03-24 | — | — | US | disclosed |
| EP-0260032-A2 | Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers | AJINOMOTO CO., INC. (JP) | 1988-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669301-B2 | Phosphoramidite building blocks for sugar-conjugated oligonucleotides | DERA, FBP1, PNKP | ADORA3 2516/4885ADORA1 3122/4885TRDMT1 389/4885 |
| US-20180362572-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | DERA, TYMP, PAICS | ADORA3 1680/4885ADORA1 2044/4885TRDMT1 269/4885 |
| US-10087208-B2 | Phosphoramidite building blocks for sugar-conjugated oligonucleotides | DERA, TYMP, PAICS | ADORA3 1680/4885ADORA1 2044/4885TRDMT1 269/4885 |
| US-20160083414-A1 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES | DERA, TYMP, PAICS | ADORA3 1680/4885ADORA1 2044/4885TRDMT1 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.